Welcome to our dedicated page for STEPAN CO SEC filings (Ticker: SCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stepan Company filings document the regulatory record for a specialty and intermediate chemicals manufacturer whose common stock trades on the New York Stock Exchange under symbol SCL. Its 8-K filings report operating results, dividend declarations, material-event disclosures, capital-structure information and exit or disposal activities tied to manufacturing and efficiency initiatives.
Stepan proxy and annual-meeting filings cover director elections, advisory compensation votes, auditor ratification, executive compensation governance and benefit-plan matters. The filing record also includes disclosure on restructuring charges, asset write-downs, decommissioning costs and other governance or financial matters reported through current reports and proxy materials.
STEPAN CO (SCL) reported insider equity activity by officer Shawn G. Lisle (VP GC & Secretary). On 2026-08-26, Lisle exercised 1,154 restricted stock units (RSUs), receiving an equal number of common shares per the award terms. To cover tax liability on the RSU vesting, 339 common shares were withheld at $62.345 per share. Following the exercise, Lisle holds 2,308 RSUs, each representing a contingent right to receive one share of Stepan common stock.
Stepan Co senior vice president and chief financial officer Ruben Dario Velasquez reported the vesting and settlement of 1,358 Restricted Stock Units (RSUs) on August 10, 2026. Each RSU represented a contingent right to receive one share of common stock, and the RSUs were settled in common shares at a reference price of $64.675 per share. In connection with the vesting, 398 common shares were withheld to satisfy tax liabilities, with the remainder retained as directly owned common stock. After the derivative transaction, 2,716 RSUs remained outstanding, vesting ratably over three years beginning on the award date.
Stepan Company reported stronger Q2 2026 results, with net sales of $ 684,109 (in thousands) up from $ 594,689, gross profit of $ 99,982, operating income of $ 37,210 and net income of $ 22,911, or $ 1.00 per basic and diluted share.
For the first six months of 2026, net sales were $ 1,288,618 (in thousands) versus $ 1,187,944, but a business restructuring charge of $ 70,545 and higher unallocated corporate expenses drove an operating loss of $ ( 12,412 ) and a net loss of $ ( 18,495 ), compared with net income of $ 31,052 a year earlier.
Operating cash flow for the six months was $ 25,298 (in thousands), capital expenditures were $ 54,294, cash and cash equivalents were $ 113,705, and total debt including current maturities was $ 647,571 at June 30, 2026. The company accrued environmental and legal reserves of $ 19,619 within an estimated loss range up to $ 46,483.
Stepan Company VP, Controller & PAO Matthew John Eaken filed an initial statement of beneficial ownership reporting 9,319 shares of Stepan common stock held directly and 3,102 shares held indirectly through an ESOP II Trust. He also reports a portfolio of stock options and stock appreciation rights on Stepan common stock with exercise prices between $50.06 and $123.73, plus performance share and restricted stock unit awards, each representing contingent rights to receive Stepan common shares based on vesting schedules or performance goals.
Stepan Company reported strong second‑quarter 2026 results, with net sales of $684.1 million, up 15% year‑over‑year. Net income more than doubled, with diluted earnings per share of $1.00. Adjusted earnings per share were $1.18, more than double the prior‑year quarter, and consolidated adjusted EBITDA rose 45% to $74.4 million, driven mainly by Surfactants and Polymers volume growth and margin recovery.
For the first half of 2026, reported results reflected $70,545 thousand of Business Restructuring expense tied to Project Catalyst, leading to a reported net loss even as adjusted net income rose 20%. The Board approved a plan to reduce the global salaried workforce by around 100 roles, expecting approximately $4–6 million of primarily cash restructuring charges, largely in the second half of 2026, within the previously disclosed $75–80 million full‑year Project Catalyst range.
Director Jan Stern Reed resigned from the Board and its committees without a disagreement, and new committee chairs were appointed. Matthew J. Eaken was named Principal Accounting Officer. The Board declared a quarterly dividend of $0.395 per share, payable September 15, 2026. Management stated that, despite macro uncertainties, they believe the company will deliver full‑year adjusted EBITDA growth, positive free cash flow and continued balance‑sheet de‑leveraging in 2026.
Stepan Company VP and GM Surfactants-INT Robin Joseph Weitkamp reported routine compensation-related equity activity involving restricted stock units (RSUs) and common stock.
On May 11, 2026, 90 RSUs were settled into 90 shares of common stock per the award terms. To cover tax obligations on the RSU vesting, 50 shares of common stock were withheld at a value of $52.58 per share, leaving 40 shares of common stock held directly after the transactions. The filing also shows 96.9 shares of common stock held indirectly through the ESOP II Trust.
Stepan Company vice president, general counsel and secretary Shawn G. Lisle reported equity compensation awards and a correction to a prior filing. On March 2, 2026, he received 6,440 stock appreciation rights with a conversion price of $50.06, 2,247 performance shares, and 4,495 restricted stock units, each tied to one share of common stock. A separate February 27, 2026 entry shows a grant of 25.544 shares of common stock at $52.51 per share. The amendment updates the previously reported stock appreciation right exercise price from $17.47 to $50.06; all other terms remain unchanged.
Stepan Co VP & CHRO Andrea Jean Barry reported equity-based compensation grants and a correction to a prior filing. On March 2, 2026, she received 6,440 stock appreciation rights with a conversion price of $50.06, 2,247 performance shares, and 4,495 restricted stock units, each tied to one share of common stock. The RSUs vest ratably over three years, while the performance shares vest if Stepan Company certifies that certain performance goals are achieved for the period ending December 31, 2028. She also acquired 16.464 shares of common stock on February 27, 2026 as a grant. This Form 4/A amends the original Form 4 only to correct the stock appreciation right conversion price to $50.06 from $17.47; all other terms of the reported transactions remain unchanged.
STEPAN CO executive Sean Thomas Moriarty, VP & GM Surfactants, reported multiple equity-based compensation awards. On March 2, 2026, he received 4,495 restricted stock units, 2,247 performance shares, and 6,440 stock appreciation rights with a $50.06 exercise price. On February 27, 2026, he also acquired 56.765 shares of common stock as an award. The filing shows 14,205.2335 common shares held directly and 4,478.351 shares held indirectly through an ESOP II trust as of that date. This Form 4/A amends a prior filing solely to correct the stock appreciation right exercise price from $17.47 to $50.06; all other terms remain unchanged.
STEPAN CO executive Richard Finn, V.P. and General Manager of Polymers, reported new equity compensation awards. He received a stock appreciation right covering 7,155 shares of common stock with a conversion price of $50.06 per share, expiring on March 3, 2036. He was also granted 2,497 performance shares and 4,994 restricted stock units, each representing the right to receive one share of common stock, with the performance shares tied to goals for a period ending December 31, 2028. The RSUs and certain awards vest ratably over three years starting on the grant date.
This amended Form 4 corrects the previously reported conversion price of the stock appreciation right from $17.47 to $50.06; all other terms of the transaction remain unchanged. Following these awards, Finn reports 241,395.915 shares of common stock held directly, along with additional indirect holdings through an ESOP trust, a personal trust, and family accounts.